Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 9/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13714165 | 1.00 | TAS2R14 (0.59) | TAS2R14MAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5315438 | 0.93 | TAS2R14 (0.56) | TAS2R14MAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13714179 | 0.91 | TAS2R14 (0.59) | TAS2R14MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL3853015 | 0.91 | TAS2R14 (0.72) | TAS2R14MAPK1MEN1KMT2A | |
| SCHEMBL3856007 | 0.90 | MAPK1 (0.52) | TAS2R14MAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3858876 | 0.89 | TAS2R14 (0.55) | TAS2R14MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL3853063 | 0.89 | TAS2R14 (0.76) | TAS2R14MAPK1 | |
| SCHEMBL3856963 | 0.88 | TAS2R14 (0.66) | TAS2R14MAPK1MEN1KMT2A | |
| SCHEMBL5337346 | 0.86 | TAS2R14 (0.52) | TAS2R14MAPK1SMN1; SMN2 | |
| SCHEMBL3860040 | 0.86 | TAS2R14 (0.63) | TAS2R14MAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579504-B2 | ABCA1 elevating compounds | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | claimed |
| US-20070203245-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | claimed |
| US-7579504-B2 | ABCA1 elevating compounds | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070203245-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007067817-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203245-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | TAS2R14 4736/4885MAPK1 3135/4885SMN1; SMN2 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.